CD40 ligand in coronary heart disease patients with Type 2 diabetes mellitus

The levels of soluble CD40L (sCD40L) and other inflammatory and thrombotic markers were studied in coronary heart disease (CHD)) patients with or without Type 2 diabetes mellitus (DM-2). In total, 56 patients with various CHD forms, as well as 10 healthy volunteers, were examined. In 12 patients, CD...

Full description

Bibliographic Details
Main Authors: O. P. Shevchenko, O. F. Prirodova, O. V. Orlova, A. O. Shevchenko
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2006-10-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/1944
_version_ 1797857224241971200
author O. P. Shevchenko
O. F. Prirodova
O. V. Orlova
A. O. Shevchenko
author_facet O. P. Shevchenko
O. F. Prirodova
O. V. Orlova
A. O. Shevchenko
author_sort O. P. Shevchenko
collection DOAJ
description The levels of soluble CD40L (sCD40L) and other inflammatory and thrombotic markers were studied in coronary heart disease (CHD)) patients with or without Type 2 diabetes mellitus (DM-2). In total, 56 patients with various CHD forms, as well as 10 healthy volunteers, were examined. In 12 patients, CD-2 was diagnosed. In all participants, the levels of high-sensitive С-reactive protein (hsCRP), fibrinogen, tumor necrosis factor-alpha (TNO-alpha), pregnancy-associated plasma protein A (PAPP-A), soluble vascular cell adhesion molecule-1 (s VCAM-1), and sCD40I were measured. Inpatients with CHD and DM-2 (Group I, n = 12), sCD40I levels were significantly higher than in CHD patients without DM-2 (Group II, n = 44), or control group: 3,07 ± 2,03, 1,72 ± 1,54, and 1,05 ± 1,07 ng/ml, respectively (p < 0, 05). Other marker levels were similar in Groups land II There was no significant sCD40I level difference among subgroups with various CHD forms. Among other cardiovascular risk factors, sCD40L levels correlated significantly with plasma triglyceride levels (p = 0,028; r = -0,301). CHD patients with DM-2 demonstrated significantly higher sCD40L plasma levels, in comparison with diabetes-free CHD patients or healthy individuals, regardless of CHD form or main cardiovascular risk factors.
first_indexed 2024-04-09T20:54:19Z
format Article
id doaj.art-7c46ec53dcba496caada10585b68b4c6
institution Directory Open Access Journal
issn 1560-4071
2618-7620
language Russian
last_indexed 2024-04-09T20:54:19Z
publishDate 2006-10-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj.art-7c46ec53dcba496caada10585b68b4c62023-03-29T21:23:13Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202006-10-010523281702CD40 ligand in coronary heart disease patients with Type 2 diabetes mellitusO. P. Shevchenko0O. F. Prirodova1O. V. Orlova2A. O. Shevchenko3Российский государственный медицинский университет, кафедра кардиологии ФУВ; Клиническая больница управления делами Президента РФ; НИИ Трансплантологии и искусственных органовРоссийский государственный медицинский университет, кафедра кардиологии ФУВ; Клиническая больница управления делами Президента РФ; НИИ Трансплантологии и искусственных органовРоссийский государственный медицинский университет, кафедра кардиологии ФУВ; Клиническая больница управления делами Президента РФ; НИИ Трансплантологии и искусственных органовРоссийский государственный медицинский университет, кафедра кардиологии ФУВ; Клиническая больница управления делами Президента РФ; НИИ Трансплантологии и искусственных органовThe levels of soluble CD40L (sCD40L) and other inflammatory and thrombotic markers were studied in coronary heart disease (CHD)) patients with or without Type 2 diabetes mellitus (DM-2). In total, 56 patients with various CHD forms, as well as 10 healthy volunteers, were examined. In 12 patients, CD-2 was diagnosed. In all participants, the levels of high-sensitive С-reactive protein (hsCRP), fibrinogen, tumor necrosis factor-alpha (TNO-alpha), pregnancy-associated plasma protein A (PAPP-A), soluble vascular cell adhesion molecule-1 (s VCAM-1), and sCD40I were measured. Inpatients with CHD and DM-2 (Group I, n = 12), sCD40I levels were significantly higher than in CHD patients without DM-2 (Group II, n = 44), or control group: 3,07 ± 2,03, 1,72 ± 1,54, and 1,05 ± 1,07 ng/ml, respectively (p < 0, 05). Other marker levels were similar in Groups land II There was no significant sCD40I level difference among subgroups with various CHD forms. Among other cardiovascular risk factors, sCD40L levels correlated significantly with plasma triglyceride levels (p = 0,028; r = -0,301). CHD patients with DM-2 demonstrated significantly higher sCD40L plasma levels, in comparison with diabetes-free CHD patients or healthy individuals, regardless of CHD form or main cardiovascular risk factors.https://russjcardiol.elpub.ru/jour/article/view/1944coronary heart deseasetype 2 diabetes mellitusinflammatory and thrombotic markers
spellingShingle O. P. Shevchenko
O. F. Prirodova
O. V. Orlova
A. O. Shevchenko
CD40 ligand in coronary heart disease patients with Type 2 diabetes mellitus
Российский кардиологический журнал
coronary heart desease
type 2 diabetes mellitus
inflammatory and thrombotic markers
title CD40 ligand in coronary heart disease patients with Type 2 diabetes mellitus
title_full CD40 ligand in coronary heart disease patients with Type 2 diabetes mellitus
title_fullStr CD40 ligand in coronary heart disease patients with Type 2 diabetes mellitus
title_full_unstemmed CD40 ligand in coronary heart disease patients with Type 2 diabetes mellitus
title_short CD40 ligand in coronary heart disease patients with Type 2 diabetes mellitus
title_sort cd40 ligand in coronary heart disease patients with type 2 diabetes mellitus
topic coronary heart desease
type 2 diabetes mellitus
inflammatory and thrombotic markers
url https://russjcardiol.elpub.ru/jour/article/view/1944
work_keys_str_mv AT opshevchenko cd40ligandincoronaryheartdiseasepatientswithtype2diabetesmellitus
AT ofprirodova cd40ligandincoronaryheartdiseasepatientswithtype2diabetesmellitus
AT ovorlova cd40ligandincoronaryheartdiseasepatientswithtype2diabetesmellitus
AT aoshevchenko cd40ligandincoronaryheartdiseasepatientswithtype2diabetesmellitus